{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:03:10Z","timestamp":1788044590516,"version":"build-2784847793"},"reference-count":16,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A simple, feasible, isocratic elution, and stable reversed-phase high performance liquid chromatography method was established and verified. The chromatographic conditions are as follows: EF-C18H, 4.6 \u00d7 250 mm, 5 \u03bcm column; column temperature 30 \u00b0C; for the mobile phase 27.2 g of KH2PO4 and 8.5 g of tetrabutylammonium hydrogen sulfate were taken, 2500 mL of water was added to dissolve, and the pH was adjusted to 6.7 with phosphoric acid:methanol solution with a ratio of 84:16 (V:V). The flow rate was 1.0 mL\/min; the injection volume was 10 \u03bcL; and the wavelength was 262 nm. According to the current ICH guidelines, the developed method was verified, and the system suitability, specificity, LOD, LOQ, linearity, range, accuracy, repeatability, durability, and solution stability of the proposed method were verified. The validation results demonstrated that the LOQ for the method was 0.05% and the LOD was 0.02%. The content was detected within the concentration range of 300 to 900 \u03bcg\/mL. The relationship between concentration and measurement was linear, with an r2 of &amp;gt;0.999. The concentration of impurities ranged from 0.3 to 4.5 \u03bcg\/mL. A good linear correlation was observed within the range of g\/mL, with a coefficient of determination r2 greater than 0.999. The accuracy and repeatability met the specified criteria.<\/jats:p>","DOI":"10.1021\/acsomega.3c06658","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T16:13:01Z","timestamp":1706199181000},"page":"10160-10168","source":"Crossref","is-referenced-by-count":5,"title":["Validation of an Ion-Pair Reverse Phase High-Performance Liquid Chromatography Method for the Detection of Major\nComponents and Related Substances in Diquafosol Sodium Eye Drops"],"prefix":"10.1021","volume":"9","author":[{"given":"Jingmin","family":"Wu","sequence":"first","affiliation":[{"name":"First People\u2019s Hospital of Linping District , ,","place":["Hangzhou, China, 311100"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huina","family":"Zhang","sequence":"additional","affiliation":[{"name":"Fuan Pharmaceutical Group Ningbo Team Pharmaceutical, Co., Ltd , ,","place":["Ningbo, China, 315201"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Zhao","sequence":"additional","affiliation":[{"name":"Fuan Pharmaceutical Group Ningbo Team Pharmaceutical, Co., Ltd , ,","place":["Ningbo, China, 315201"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benkai","family":"Qin","sequence":"additional","affiliation":[{"name":"Fuan Pharmaceutical Group Ningbo Team Pharmaceutical, Co., Ltd , ,","place":["Ningbo, China, 315201"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Lou","sequence":"additional","affiliation":[{"name":"Tongde Hospital of Zhejiang Province , ,","place":["Hangzhou, China, 310012"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5594-4226","authenticated-orcid":true,"given":"Yonghua","family":"Yu","sequence":"additional","affiliation":[{"name":"Fuan Pharmaceutical Group Ningbo Team Pharmaceutical, Co., Ltd , ,","place":["Ningbo, China, 315201"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Huang","sequence":"additional","affiliation":[{"name":"Fuan Pharmaceutical Group Ningbo Team Pharmaceutical, Co., Ltd , ,","place":["Ningbo, China, 315201"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangmin","family":"Cheng","sequence":"additional","affiliation":[{"name":"Fuan Pharmaceutical Group Ningbo Team Pharmaceutical, Co., Ltd , ,","place":["Ningbo, China, 315201"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangyu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Fuan Pharmaceutical Group Ningbo Team Pharmaceutical, Co., Ltd , ,","place":["Ningbo, China, 315201"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"issue":"2","key":"2026081709114627300_cit1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1542-0124(12)70082-4","article-title":"The epidemiology of dry eye disease: Report of the epidemiology subcommittee\nof the international Dry Eye WorkShop (2007)","volume":"5","author":"Janine","year":"2007","journal-title":"Ocul. Surf."},{"key":"2026081709114627300_cit2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10384-010-0812-2","article-title":"Dry Eye Survey\nGroup of the National\nHospital Organization of Japan. Association between clinical diagnostic\ntests and health-related quality of life surveys in patients with\ndry eye syndrome","volume":"54","author":"Mizuno","year":"2010","journal-title":"Jpn. J. Ophthalmol."},{"issue":"7","key":"2026081709114627300_cit3","first-page":"119","article-title":"Chinese\nPrimary Health Care","volume":"28","author":"Shi","year":"2014","journal-title":"Int. J. Environ. Res. Public\nHealth"},{"issue":"1","key":"2026081709114627300_cit4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.tvjl.2014.05.022","article-title":"Conjunctival expression\nof the P2Y2 receptor and the effects of 3% diquafosol ophthalmic solution\nin dogs.[J]","volume":"202","author":"Terakado","year":"2014","journal-title":"Veterinary Journal"},{"key":"2026081709114627300_cit5","doi-asserted-by":"publisher","first-page":"C595","DOI":"10.1152\/ajpcell.2001.281.2.C595","article-title":"Rabbit conjunctival epithelium transports\nfluid, and\nP2Y2 receptor agonists stimulate Cl- and fluid secretion","volume":"281","author":"Li","year":"2001","journal-title":"Am. J. PhysiolCell Physiol."},{"key":"2026081709114627300_cit6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1006\/exer.1998.0520","article-title":"Regulation of ocular\nmucin secretionby P2Y2 nucleotide\nreceptors in rabbit and human conjunctiva","volume":"67","author":"Jumblatt","year":"1998","journal-title":"Exp.\nEye Res."},{"key":"2026081709114627300_cit7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000076887","article-title":"Diquafosol elicits\nincreases in net cl- transport through p2Y2 receptor stimulation in\nrabbit conjunctiva","volume":"36","author":"Murakami","year":"2004","journal-title":"Ophthalmic Res."},{"issue":"5","key":"2026081709114627300_cit8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s10384-013-0251-y","article-title":"Long-term results of\ntreatment with diquafosol ophthalmic solution for aqueous-deficient\ndry eye\u00ad[J]","volume":"57","author":"Koh","year":"2013","journal-title":"Japanese journal of ophthalmology"},{"key":"2026081709114627300_cit9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4103\/0976-500X.162004","article-title":"International\nconference on harmonization of technical requirements for registration\nof pharmaceuticals for human use.[J]","author":"Singh","year":"2015","journal-title":"J. Pharmacol.\nPharmacotherap."},{"issue":"5","key":"2026081709114627300_cit10","first-page":"56","article-title":"Forced degradation\nas an integral part of HPLC stability-indicating method development\u00ad[J]","volume":"10","author":"Ngwa","year":"2010","journal-title":"Drug Delivery Technol."},{"issue":"4","key":"2026081709114627300_cit11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jpba.2004.08.008","article-title":"ICH guidance in practice: establishment of inherent stability of\nsecnidazole and development of a validated stability-indicating high-performance\nliquid chromatographic assay method\u00ad[J]","volume":"36","author":"Bakshi","year":"2004","journal-title":"J. Pharm.\nBiomed Anal"},{"key":"2026081709114627300_cit12","first-page":"18","article-title":"Impurities and Forced\nDegradation Studies: A Review\u00ad[J]","author":"C\nKogawa","year":"2016","journal-title":"Curr. Pharm.\nAnal."},{"key":"2026081709114627300_cit13","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jpha.2013.09.003","article-title":"Analytical\nmethod development and validation of olmutinib bulk drug as per ICH\nQ2 guidelines by using RP-HPLC","author":"Khandare","year":"2019","journal-title":"J. Drug Delivery\nTherap."},{"issue":"4","key":"2026081709114627300_cit14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.pharma.2020.11.003","article-title":"A systematic approach for stability-indicating\nHPLC method optimization\nfor Nilotinib bulk through design of experiments: Application towards\ncharacterization of base degradation products by mass spectrometry\n- ScienceDirect\u00ad[J]","volume":"79","author":"Narenderan","year":"2021","journal-title":"Ann. Pharm. Franc\u0327aises"},{"key":"2026081709114627300_cit15","unstructured":"Galushko, S.\n          , Honsberg, R.. Automated method\ndevelopment using Agilent 1100 Series HPLC systems, Agilent ChemStation and ChromSword\u00aesoftware.https:\/\/www.agilent.com\/en-us\/Agilent404?s=https:\/\/www.agilent.com\/Library\/applications\/5988-8927EN.pdf."},{"key":"2026081709114627300_cit16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13321-018-0259-x","article-title":"Key features\nand updates for Origin\n2018","volume":"10","author":"Moberly","year":"2018","journal-title":"J. Cheminform"}],"container-title":["ACS Omega"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsomega.3c06658","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/9\/9\/10160\/4429957\/ao3c06658.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/9\/9\/10160\/4429957\/ao3c06658.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:31:04Z","timestamp":1786973464000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/acsodf\/article\/9\/9\/10160\/411127\/Validation-of-an-Ion-Pair-Reverse-Phase-High"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,1,25]]},"published-print":{"date-parts":[[2024,3,5]]}},"URL":"https:\/\/doi.org\/10.1021\/acsomega.3c06658","relation":{},"ISSN":["2470-1343"],"issn-type":[{"value":"2470-1343","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]}}}